Brian J Czerniecki
Brian J Czerniecki is an expert in Oncology at Moffitt Cancer Center (United States). As of October 2026, ScienceLeadR ranks Brian J Czerniecki in the top 1% of experts worldwide for Breast Diseases and Breast Neoplasms. Brian J Czerniecki has authored 339 publications, the most recent in 2026, and is an investigator in 11 clinical trials, 2 of them ongoing. SLR score: 1,295 (community average: 125). How the SLR is computed.
LeadR Profile
Oncology
Subspecialties: Neurology - Immunology - Surgery
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1997 - 2026
Number : 339
Citations
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| ASO Visual Abstract: An International Randomized Prospective Trial Comparing a Supine MRI-based Guidance System, The Breast Cancer Locator TM , to Wire Localization for Breast-Conserving Surgery for Nonpalpable Breast Cancer. PMID 42945019 — breast neoplasms, neoplasms, breast | Ann Surg Oncol | 2026 | 0 |
| Preoperative Prediction of Ductal Carcinoma In Situ Upstaging Using Machine Learning-Based Peritumoral Breast MRI Radiomics. PMID 42786920 — research design, breast neoplasms, carcinoma, ductal, neoplasms, magnetic resonance imaging, biopsy, machine learning, carcinoma, intraductal, noninfiltrating, breast, learning, wounds and injuries, carcinoma in situ | J Magn Reson Imaging | 2026 | 1 |
| A Cohort Study of the Effectiveness of Trastuzumab Deruxtecan for Treating Metastatic Progressive HER2-Positive Breast Cancer. PMID 42418955 — breast neoplasms, neoplasms, cohort studies, breast, trastuzumab | Clin Breast Cancer | 2026 | 0 |
| Breaking the Immune Sanctuary: Targeting Metastatic Niches. PMID 42208002 — cells, neoplasms, multiple chronic conditions, liver, immunotherapy, therapeutics | Am Soc Clin Oncol Educ Book | 2026 | 0 |
| Outcomes After Intratumoral Delivery of Immunotherapy in Breast Cancer. PMID 42130226 — injections, safety, breast neoplasms, neoplasms, oncolytic viruses, immunotherapy, breast, therapeutics, dendritic cells | J Surg Oncol | 2026 | 0 |
Clinical Studies 11
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Ongoing Clinical Trials
2 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Study of HER2 Directed Dendritic Cell (DC1) Vaccine Weekly Paclitaxel Trastuzumab Pertuzumab NCT05325632 — cells, albumin-bound paclitaxel, epidermal growth factor, mastectomy, growth, vaccines, breast neoplasms, paclitaxel, neoplasms, mastectomy, segmental, receptors, growth factor, breast, therapeutics, dendritic cells, trastuzumab | Phase 2 | Recruiting | 2021 |
| Study of Screening Brain MRIs in Stage IV Breast Cancer NCT05115474 — triple negative breast neoplasms, breast neoplasms, brain, neoplasms, magnetic resonance imaging, hormones, breast | Phase 2 | Recruiting | 2021 |
LeadR Networks
Main global connection map